I am so disappointed in one way that BOT has sought to close off their acne trials now especially with one week to go before Christmas. Why did they choose such a pithy small sample when we all know the absolute rubbish young teenagers will be eating over the next two week period will hopefully have led their faces to look like one of those Masseur sandals with all those bumps.
Our Matt has missed a golden opportunity to show off how good BTX 1503 will be by not allowing youthful exuberance to culminate in a pimply face, one that an unfortunate Braille student could read and say - you've eaten too much fatty foods kiddy being careful not to poke the kids eyes out.
But their is light at the end of the tunnel, there is sun at the end of a rainy day, every cloud has a silver lining. You get it. Phase 2 trials in the United Stated in the first half of next year.
Ladies and gentleman I give you ninety million dollars. So long as it sucks seeds like my friends old parrot.
After that folks, we have the dermatitis study. Big pharma will be lining up and when that moment occurs, I hope Matt will be a good negotiator for us all.
Too early for an Aperol spritzer ?
BOT Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)